First-line paclitaxel and carboplatin in persistent/recurrent or advanced cervical cancer: A retrospective analysis of patients treated at Brazilian National Cancer Institute

International Journal of Gynecological Cancer

Volumn 23, Issue 4, 2013, Pages 743-748

  Garces, Álvaro Henrique Ingles ^a   Mora, Paulo Alexandre Ribeiro ^a   Alves, Flávia Vieira Guerra ^a   Do Carmo, Claudio Calazan ^a   Grazziotin, Rachele ^a   Fernandes, Anna Cristina Ferrão Mangia ^a   Nogueira Rodrigues, Angélica ^a   De Melo, Andréia Cristina ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Carboplatin; Cervical cancer; Paclitaxel; Palliative chemotherapy

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; BRAZIL; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CONSTIPATION; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG INTOXICATION; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERINE CERVIX CANCER; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAZIL; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84879981981     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31828c141d     Document Type: Article

References (25)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v2.0. Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available at: http://globocan.iarc.fr. Accessed July 20, 2012.
2. Mathers C, Boerma T, Ma Fat D. The global burden of disease: 2004 update (Geneva, Switzerland:World Health Organization); 2008. Available at: http://www.who.int/healthinfo/global-burden-disease/GBD-report-2004update-full. pdf. Accessed July 20, 2012.
3. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-2150.
4. Forouzanfar MH, Foreman KJ, de los Santos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378:1461-1484.
5. Rio de Janeiro (RJ) Instituto Nacional do Câncer-Brasil. Estimativa 2012-Incidência do Câncer no Brasil. Available at: http://www1.inca.gov.br/estimativa/2012/index.asp?ID=5. Accessed July 20, 2012.
6. Quinn MA, Benedet JL, Odicino F. Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95:S43-S103.
7. Rose PG, Lessing JA, Gershenson DM, et al. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 1999;17:2676-2680.
8. Blessing JA, Stehman FB, McGehee R. A phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group study). Invest New Drugs. 1986;4:187-191.
9. Thigpen T. The role of chemotherapy in the management of carcinoma of the cervix. Cancer J. 2003;9:425-432.
10. Lhomme C, Fumoleau P, Fargeot P, et al. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clin Oncol. 1999;17:3136-3142.
11. Look KY, Blessing JA, Levenback C, et al. trial of CPT-11 in recurrent squamous carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1998;70:334-338.
12. Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2009;27:1069-1074.
13. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22:3113-3119.
14. Long HJ, Bundy BN, Grendys EC, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2005;23:4626-4633.
15. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649-4655.
16. Weiss GR, Green S, Hannigan EV, et al. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. Gynecol Oncol. 1990;39:332-336.
17. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecological oncology group study. J Clin Oncol. 2003;21:3194-3200.
18. Kitagawa R, Katsumata N, Yamanaka Y, et al Shizuoka Cancer Center. Phase II trial of paclitaxel (T) and carboplatin (C) in patients with recurrent or metastatic cervical carcinoma. ASCO Annual Meeting Proceedings (post-meeting edition). J Clin Oncol. 2004;22:5048.
19. Kitagawa R, Katsumata N, Shibata T, et al and Japan Clinical Oncology Group. A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVB, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505). ASCO Annual Meeting Proceedings (post-meeting edition). J Clin Oncol. 2012;30:5006.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
21. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) [Internet]. August 9, 2006. Available at: http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/docs/ctcaev3.pdf. Accessed July 20, 2012.
22. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748-1756.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
24. Carmo CC, Luiz RRH. Indication of radiotherapy for women with cervical cancer in Rio De Janeiro, Brazil. Int J Gynecol Cancer. 2010;20:158-163.
25. Tanioka M, Katsumata N, Yonemori K, et al. Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy. Cancer Chemother Pharmacol. 2011;68:337-342.